Exogenus Therapeutics Leads €13 Million EU-Funded Osteoarthritis Therapy Consortium
Exogenus Therapeutics is leading ExoCordOA, a five-year Horizon Europe-backed project to advance a secretome-based therapy for osteoarthritis.
Exogenus Therapeutics is leading ExoCordOA, a five-year Horizon Europe-backed project to advance a secretome-based therapy for osteoarthritis.